The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction Vancouver, ...

COCP READ THE FULL COCP RESEARCH REPORT Business Update Update on CDI-988 On January 8, 2025, Cocrystal Pharma, Inc.

But while platform trials have the potential to be more effective and less expensive than traditional trials, challenges ...

Strengthened the cash balance to provide runway into 2027, allowing Allarity to accelerate stenoparib's clinical development, ...

An invaluable resource is being starved to death with no scientific or ethical justification ...

A new consensus paper provides an updated evaluation of reference bone turnover markers (BTMs) and newer markers in the ...

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated ...

SmartfIRE 12-month data demonstrated 86.9% effectiveness when utilized with high adherence to the recommended ablation workflow and significant quality of life improvements using the Dual Energy ...

The DSM might be holding us back from developing better treatments. A new study attempts to uncover a more accurate ...

Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and ...

Q4 2024 Earnings Call Transcript March 31, 2025 Brainstorm Cell Therapeutics Inc. reports earnings inline with expectations.

New findings reveal Black Americans face higher multiple sclerosis, ms rates and mortality while being systematically ...